ReviewTranslational research : the journal of laboratory and clinical medicine2017
The influence of gut-derived CD39 regulatory T cells in CNS demyelinating disease.
Review in Translational research : the journal of laboratory and clinical medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intestinal Microbiota: a New Target for Chalaziosis Treatment in Children
Effect of Probiotics on the Occurrence of Blepharitis in Adults and Children
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Intestinal microbiome: a new target for chalaziosis treatment in children?European journal of pediatrics · 2021Trial
- Identification of commensal gut microbiota signatures as predictors of clinical severity and disease progression in multiple sclerosis.Scientific reports · 2024Article
- Biomolecular Mechanisms of Autoimmune Diseases and Their Relationship with the Resident Microbiota: Friend or Foe?Pathophysiology : the official journal of the International Society for Pathophysiology · 2022Review
- Current and Future Biomarkers in Multiple Sclerosis.International journal of molecular sciences · 2022Review
- Advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis.Frontiers in molecular neuroscience · 2022Review
- B Cells and Microbiota in Autoimmunity.International journal of molecular sciences · 2021Review
- Modulating Gut Microbiota: An Emerging Approach in the Prevention and Treatment of Multiple Sclerosis.Current neuropharmacology · 2021Review
- How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process.Gut microbes · 2020Article
- Tolerance regeneration by T regulatory cells in autologous haematopoietic stem cell transplantation for autoimmune diseases.Bone marrow transplantation · 2020Review
- Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis.Frontiers in immunology · 2019Article
- Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?Auto- immunity highlights · 2018Review
- Gut microbiota linked to autoimmune uveitis.Annals of eye science · 2017Article
- Immunological and Clinical Effect of Diet Modulation of the Gut Microbiome in Multiple Sclerosis Patients: A Pilot Study.Frontiers in immunology · 2017Article
- Modulation of Multiple Sclerosis and Its Animal Model Experimental Autoimmune Encephalomyelitis by Food and Gut Microbiota.Frontiers in immunology · 2017Review
- Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse.Frontiers in neurology · 2017Review
- Correlation of Gut Microbiota Composition with Resistance to Experimental Autoimmune Encephalomyelitis in Rats.Frontiers in microbiology · 2016Article
- Article
- Alzheimer's disease (AD) in multiple sclerosis (MS): A systematic review of published cases, mechanistic links between AD and MS, and possible clinical evaluation of AD in MS.Journal of Alzheimer's disease reportsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
There is considerable interest in trying to understand the importance of the gut microbiome in human diseases. The association between dysbiosis, an altered microbial composition, as related to human disease is being explored in the context of different autoimmune conditions, including multiple sclerosis (MS). Recent studies suggest that MS affects the composition of the gut microbiota by altering the relative abundances of specific bacteria and archaea species. Remarkably, some of the bacterial species shown reduced in the gut of MS patients are known to promote immunosuppressive regulatory T cells (Tregs). In MS, the function of a phenotype of Tregs that express CD39, an ectoenzyme involved in the catabolism of adenosine triphosphate as immunomodulatory cells, appears to be reduced. In this review, we discuss the involvement of the gut microbiota in the regulation of experimental models of central nervous system inflammatory demyelination and review the evidence that link the gut microbiome with MS. Further, we hypothesize that the gut microbiome is an essential organ for the control of tolerance in MS patients and a potential source for safer novel therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.